Since MGMT epigenetic analysis and protein expression is unambiguously the best genetic signature with respect to clinical outcome of glioma patients than evaluations of its mRNA45, a more reliable and reproducible methods to detect it may be developed to further augment the management of the disease with respect to chemotherapy by alkylating agents. The gene discussed is MGMT; the disease is central nervous system cancer.